X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending

By Nicole Longo  |    August 20, 2018
How big is the 340B program, and what share of the prescription medicine market does it represent? Those are popular questions of late as stakeholders discuss ways to improve the 340B program. In...   Read More

New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain

By Holly Campbell  |    August 13, 2018
An analysis published in a Health Affairs blog post by Nancy L. Yu, Preston Atteberry and Peter B. Bach of the Memorial Sloan Kettering Cancer Center reinforces that one-third of medicine list...   Read More

PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion

By Tim McClung  |    August 9, 2018
PhRMA member companies invested $71.4 billion in research and development (R&D) in 2017, the highest level of investment on record, according to the 2018 PhRMA member annual survey, released in...   Read More

How much do you know about Medicare Part B?

By Nicole Longo  |    July 31, 2018
In recent months, the Administration has proposed a number of changes to Medicare Part B. From the Department of Health and Human Services’ request for information, HHS Blueprint To Lower Drug...   Read More

Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines

By Andrew Powaleny  |    July 25, 2018
In today’s new era of medicine, America’s biopharmaceutical companies are conducting some of the most complex and difficult research in the world to develop innovative treatments for patients.   Read More

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

By Randy Burkholder  |    July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?   Read More

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

By Holly Campbell  |    July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....   Read More

Event next week: Supporting the next generation of lifesaving medicines

By Andrew Powaleny  |    July 12, 2018
The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more...   Read More

GAO again recommends improvements to 340B program

By Nicole Longo  |    July 11, 2018
Over the years, the non-partisan Government Accountability Office (GAO) has reviewed various aspects of the 340B program, finding areas for improvement and providing recommendations. The latest...   Read More

How ICER’s assessment of a new class of migraine treatments fails patients

By Lauren Neves  |    July 10, 2018
Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates